Rhumbline Advisers Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

Rhumbline Advisers lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,214,532 shares of the company’s stock after selling 31,009 shares during the quarter. Johnson & Johnson comprises approximately 0.5% of Rhumbline Advisers’ portfolio, making the stock its 22nd biggest holding. Rhumbline Advisers owned 0.18% of Johnson & Johnson worth $609,506,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PUREfi Wealth LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $1,027,000. ABC Arbitrage SA purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $1,263,000. Blue Trust Inc. increased its stake in shares of Johnson & Johnson by 28.9% in the fourth quarter. Blue Trust Inc. now owns 63,213 shares of the company’s stock worth $9,142,000 after buying an additional 14,179 shares during the period. Asset Planning Inc bought a new stake in Johnson & Johnson in the fourth quarter valued at $795,000. Finally, Vicus Capital boosted its holdings in Johnson & Johnson by 1.9% in the fourth quarter. Vicus Capital now owns 5,464 shares of the company’s stock valued at $790,000 after acquiring an additional 104 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on JNJ shares. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Barclays upped their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Guggenheim boosted their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Finally, Leerink Partners cut their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Price Performance

JNJ stock opened at $156.20 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The business’s 50-day moving average is $147.87 and its two-hundred day moving average is $155.95. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.